Original Source(s)
Related Content
FDA Expands Test for Gastric and Esophageal Cancers
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
-
2 min
Pathology Pain Points
Results of the PNPL 2026 survey reveal workforce shortages remain a top-tier concern among members
July 14, 2026
-
1 min
Reimagining Risk and Resilience
Accelerating analytical data management for the next-generation laboratory
July 8, 2026
-
7 min